New MHRA-supported research reveals patterns of vaccine-derived poliovirus spread and implications for global eradication efforts
Study provides crucial insights for targeting rapid response strategies and improving polio surveillance worldwide
-
-
MHRA approves inavolisib for the treatment of breast cancer
The MHRA has today, 26 November 2025, approved inavolisib (Itovebi) for the treatment of adults with a type of breast cancer called HR-positive
-
Class 4 Medicines Defect Notification: Lexon UK Ltd, Moclobemide 150mg tablets, EL(25)A/50
Lexon UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in the cartons for the batches listed in this notification is missing important updated safety information.
-
Three convicted in major MHRA investigation into illegal online supply of medicines
Operation Lamborghini disrupts multimillion-pound criminal network supplying controlled drugs and unauthorised medicines online
-
MHRA reaffirms safety of childhood vaccination
Vaccination is one of the most effective and safest ways to protect against many serious infectious diseases
-
Field Safety Notices: 10 to 14 November 2025
List of Field Safety Notices from 10 to 14 November 2025.
-
Research: Digital mental health technology: user and public perspectives on identifying and reporting harms
A research report on attitudes regarding identifying and reporting harms associated with the use of DMHT and awareness of the MHRA Yellow Card Scheme.
-
Class 3 Medicines Recall: Sun Pharmaceutical Industries Limited, Fingolimod SUN 0.5mg hard capsules, EL(25)A/49
Sun Pharma UK Limited is conducting a precautionary recall of a single batch of Fingolimod SUN 0.5 mg hard capsules due to reports of capsule breakage on removing from the blister. No other batches of Fingolimod SUN 0.5mg hard capsules are impacted.
-
Professor Alastair Denniston: The future regulation of AI in healthcare
Creating a framework that is safe, fast and trusted.
-
Consultation on the International Council for Harmonisation Guideline Q3E for Extractables and Leachables
The MHRA is consulting with UK stakeholders to gather feedback and comments on an international guideline on the assessment and control of extractables and leachables.
-
Multi-million pound backing for cutting edge projects by UK scientists and innovators
New government funding will help make the boldest ideas in UK life sciences a reality.
-
Guidance: Early Access to Medicines Scheme: Overview
The Early Access to Medicines Scheme (EAMS) aims to give patients with life threatening or seriously debilitating conditions early access to medicines that show early signs of having a major advantage over existing therapeutics.